These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 17320208)

  • 21. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin.
    Dropinski J; Jakiela B; Sanak M; Wegrzyn W; Biernat M; Dziedzina S; Plutecka H; Szczeklik A
    Thromb Haemost; 2007 Jul; 98(1):201-9. PubMed ID: 17598014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel anti-platelet effect: an evaluation by optical aggregometry, impedance aggregometry, and the platelet function analyzer (PFA-100).
    Dyszkiewicz-Korpanty A; Olteanu H; Frenkel EP; Sarode R
    Platelets; 2007 Nov; 18(7):491-6. PubMed ID: 17852774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.
    Fox SC; May JA; Shah A; Neubert U; Heptinstall S
    Platelets; 2009 Jun; 20(4):250-9. PubMed ID: 19440925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders.
    Manoharan A; Gemmell R; Hartwell T
    Am J Hematol; 2006 Sep; 81(9):676-83. PubMed ID: 16795055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease.
    Walter T; Szabo S; Kazmaier S; Swoboda S; Suselbeck T; Brueckmann M; Borggrefe M; Beyer ME; Hoffmeister HM
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):616-20. PubMed ID: 18574391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
    Payne CD; Li YG; Brandt JT; Jakubowski JA; Small DS; Farid NA; Salazar DE; Winters KJ
    Platelets; 2008 Jun; 19(4):275-81. PubMed ID: 18569863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug.
    Labarthe B; Théroux P; Angioï M; Ghitescu M
    J Am Coll Cardiol; 2005 Aug; 46(4):638-45. PubMed ID: 16098428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment.
    van der Stelt CA; van Werkum JW; Seesing TH; Berg JM; Hackeng CM
    Platelets; 2007 Nov; 18(7):550-3. PubMed ID: 17957573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
    Shenkman B; Matetzky S; Fefer P; Hod H; Einav Y; Lubetsky A; Varon D; Savion N
    Thromb Res; 2008; 122(3):336-45. PubMed ID: 18155752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
    Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
    Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Am J Cardiol; 2009 Nov; 104(9):1189-93. PubMed ID: 19840560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR).
    Pamukcu B; Oflaz H; Onur I; Oncul A; Ozcan M; Umman B; Mercanoglu F; Meric M; Nisanci Y
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):187-92. PubMed ID: 17287637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
    Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
    Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet aggregation and recruitment with aspirin-clopidogrel therapy.
    Helgason CM; Grossi E; Pandey D; Valika A; Cursio J; Brace LD
    Cerebrovasc Dis; 2008; 25(5):392-400. PubMed ID: 18349532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease.
    Addad F; Chakroune T; Asma A; Abderazek F; Zohra D; Ghrissi I; Hassine M; Gamra H; Elalamy I
    Thromb Res; 2009 Feb; 123(4):640-3. PubMed ID: 18602138
    [No Abstract]   [Full Text] [Related]  

  • 40. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.